Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts

Table 4 Parameter estimates and standard errors from the final time to detection of MGIT positivity model

Variable	Coefficient	SE	RSE	P value	Hazard Ratio (95% CI)
Coefficient of log₁₀ LAM Concentration^a	1.135	0.1028	9.058	0	3.111 (2.544, 3.806)
Coefficients for Treatment effects
MRZE (N = 19)	− 1.169	0.2942	25.17	7.10E−05	0.3108 (0.1746, 0.5531)
RZ (N = 20)	− 0.08365	0.2779	332.3	0.7634	0.9198 (0.5334, 1.586)
HRZE (reference) (N = 49)	0	–	–	–	–
M (N = 18)	0.4477	0.2859	63.86	0.1174	1.565 (0.8934, 2.741)
R (N = 19)	0.4543	0.2893	63.69	0.1164	1.575 (0.8934, 2.777)
HZ (N = 17)	0.6332	0.2994	47.29	0.03445	1.884 (1.047, 3.387)
H (N = 17)	0.7169	0.2879	40.15	0.01276	2.048 (1.165, 3.601)
Z (N = 18)	2.034	0.3014	14.82	1.51E−11	7.641 (4.232, 13.79)

^aHazard ratio is calculated per unit of log₁₀ LAM concentration
CI, confidence interval; H, isoniazid; HRZE, isoniazid, rifampin, pyrazinamide, and ethambutol; HZ, isoniazid and pyrazinamide; LAM, lipoarabinomannan; log₁₀, base 10 logarithm; M, moxifloxacin; N, number of records; MGIT, Mycobacterium Growth Indicator Tube; MRZE, moxifloxacin, rifampin, pyrazinamide, and ethambutol; P, probability; R, rifampin; RSE, relative standard error; RZ, rifampin and pyrazinamide; SE, standard error; Z, pyrazinamide

ISSN: 1471-2334